CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.
|Articles|July 26, 2018
Supplements and Featured Publications
- Exclusive Coverage of the American Society of Clinical Oncology Annual Meeting
Exclusive Coverage of the 2018 American Society of Clinical Oncology Annual Meeting
Advertisement
Highlights from the American Society of Clinical Oncology meeting, which took place on June 1-5, 2018 in Chicago, IL are available in this newsletter published by The American Journal of Managed Care.
Advertisement
Related to this article
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Debra Patt, MD, PhD, MBA, MPH, discusses AI adoption, administrative burden, and strategies to streamline prior authorization in oncology.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data: FACT vs Non-FACT CAR T Outcomes Compared
2
FDA Approves First Treatment for Sanfilippo Syndrome Type A
3
FDA Approves Imlunestrant Plus Abemaciclib for Breast Cancer
4
Higher CPAP Adherence Linked With Lower Mortality Risk in OSA
5